#COMPREHENSIVE META ANALYSIS 3.3070 TRIAL#
#COMPREHENSIVE META ANALYSIS 3.3070 PC#

#COMPREHENSIVE META ANALYSIS 3.3070 PC#

In two randomized trials (HORRAD and STAMPEDE Arm-H), the effectiveness of local radiotherapy was evaluated in patients with de novo metastatic hormone-sensitive PC (mHSPC) but no significant survival advantage was reported. , In addition, in the TITAN trial, apalutamide, an androgen-receptor inhibitor of the ligand-binding domain, in combination with ADT resulted in significantly higher OS rate as compared with ADT.

#COMPREHENSIVE META ANALYSIS 3.3070 TRIAL#

, Moreover, enzalutamide plus ADT was associated with significantly higher rates of OS in the ENZAMET trail however, in the result of the interim analysis of the ARCHES trial in phase III, a comparison of enzalutamide plus ADTвЂ“an androgen-receptor inhibitorвЂ“and ADT yielded no difference in OS. According to the results of the LATITUDE and STAMPEDE Arm-G trials conducted in 2019, the improvement in median overall survival (OS) was significantly improved by the addition of AA plus prednisone to ADT. Food and Drug Administration also approved abiraterone acetate (AA) plus prednisone, an androgen synthesis inhibitor, in combination with ADT for upfront treatment of metastatic high-risk castration-naive PC. Despite the fact that no GETUG-AFU trial has ever demonstrated a survival advantage, in CHAARTED and STAMPEDE Arm-C trials, use of docetaxel plus ADT was superior to only ADT. On diagnosis, androgen-deprivation therapy (ADT) is the gold standard in castration-naive metastatic PC (mPC).

Prostate cancer (PC) is the second leading cancer type in men and accounts for 29.3 new cases per 100,000 men in the world it is also the sixth leading cause of cancer deaths in men. The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis.

Keywords:В High-volume prostate cancer, hormone-sensitive prostate cancer, low-volume prostate cancer, network meta-analysis, second-generation antiandrogenes Depending on the patient's tolerance, in high-volume mHSPC, docetaxel, or apalutamide in combination with ADT could be alternatives for AA, whereas in the low-volume mHSPC, local radiotherapy plus ADT or ADT alone could be utilized in place of enzalutamide. AA plus prednisone in high-risk and high-volume-mHSPC patients and enzalutamide in low-volume-mHSPC patients could be favorable options in combination with ADT. In addition, in the high-volume and general-population settings (all trials and cases), AA was superior to ADT (HR = 1.568, 95% CrI: 1.378вЂ“1.773 and HR = 1.164, 95%CrI: 1.348вЂ“1.924, respectively).Д¬onclusion: The volume status based on the CHAARTED trial should be taken into account to determine an appropriate treatment strategy for mHSPC. In addition, in the low-volume and docetaxel-naive settings, enzalutamide was superior to ADT (hazard ratio = 0.429, 95% CrI: 0.258вЂ“0.714 and HR = 0.533, 95% CrI: 0.375вЂ“0.756, respectively). Results: In combination with ADT, abiraterone acetate (AA) in the general-population and high-volume-disease subgroups, and enzalutamide in docetaxel-naive and low-volume-disease subgroups have the highest probability of being the best treatment modalities in terms of overall survival.

The analysis was performed for all mHSPC cases as well as for low- and high-volume and docetaxel-naive subgroups. Materials and Methods: A total of 10 trials investigating different treatment modalities were conducted using NMA. In this analysis, we aimed to determine the most effective approach for treating and suppressing mHSPC using network meta-analysis (NMA). In addition to androgen-deprivation therapy (ADT), new generation agents have provided survival advantages to patients with metastatic hormone-sensitive PC (mHSPC). Source of Support: None, Conflict of Interest: NoneД«ackground: Prostate cancer (PC) is one of the most common cancer types in men.

The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysisДЎВ Department of Oncology, School of Medicine, Istinye University, Istanbul, TurkeyДўВ Department of Oncology, Lara medicalpark Hospital, Antalya, TurkeyДepartment of Oncology, School of Medicine, Istinye University, Maltepe, Г‡Д±rpД±cД± Yolu B Г‡k.

Comprehensive meta analysis 3.3070